Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Notified of DEA Clearance for Import of High-Purity, Pharmaceutical-Grade Cannabidiol (CBD)

Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Notified of DEA Clearance for Import of High-Purity, Pharmaceutical-Grade Cannabidiol (CBD)

U.S. Phyto-Medical Company Clears Regulatory Hurdle in Its Ongoing Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat HE and CTE SAN DIEGO, March 01, 2016 (GLOBE NEWSWIRE) — Medical Marijuana, Inc....
Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy

Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy

Kannalife Sciences, Inc., a Phyto-Medical Company™ has found through its research that KLS-13019 is 50x More Potent and Over 400-Fold Safer Than CBD SAN DIEGO, CA – February 18, 2016 – Medical Marijuana, Inc. (OTC Pink: MJNA) is pleased to announce that the Company’s...